DaVita Inc. (NYSE:DVA) Receives $166.33 Consensus Price Target from Brokerages

DaVita Inc. (NYSE:DVA) has been given a consensus rating of “Hold” by the six research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $166.33.

Several analysts have recently commented on DVA shares. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a research note on Friday, February 21st. Barclays increased their price target on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 18th. Finally, Cowen reissued a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th.

DaVita Stock Performance

NYSE DVA opened at $150.00 on Friday. The firm has a market cap of $12.00 billion, a price-to-earnings ratio of 13.97, a PEG ratio of 1.07 and a beta of 0.99. The company has a 50 day moving average of $158.73 and a 200-day moving average of $157.55. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. DaVita has a 1-year low of $125.64 and a 1-year high of $179.60.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, equities analysts forecast that DaVita will post 10.76 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DaVita

Hedge funds and other institutional investors have recently bought and sold shares of the business. Epoch Investment Partners Inc. bought a new position in shares of DaVita during the fourth quarter worth $55,100,000. Invesco Ltd. boosted its position in shares of DaVita by 20.9% during the fourth quarter. Invesco Ltd. now owns 1,589,545 shares of the company’s stock worth $237,716,000 after purchasing an additional 275,284 shares in the last quarter. Iron Triangle Partners LP bought a new position in shares of DaVita during the fourth quarter worth $38,946,000. Amundi boosted its position in shares of DaVita by 116.4% during the fourth quarter. Amundi now owns 446,386 shares of the company’s stock worth $68,726,000 after purchasing an additional 240,126 shares in the last quarter. Finally, Bridgewater Associates LP raised its holdings in shares of DaVita by 298.4% during the fourth quarter. Bridgewater Associates LP now owns 239,970 shares of the company’s stock worth $35,888,000 after acquiring an additional 179,744 shares during the period. 90.12% of the stock is owned by institutional investors.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.